Tech Company Financing Transactions
Eiger BioPharmaceuticals Funding Round
On 2/24/2009, Eiger BioPharmaceuticals raised $7.1 million in Series A funding from InterWest Partners and Vivo Capital.
Transaction Overview
Company Name
Announced On
2/24/2009
Transaction Type
Venture Equity
Amount
$7,100,000
Round
Series A
Investors
Proceeds Purpose
The funding will advance the company's lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2155 Park Blvd.
Palo Alto, CA 94306
USA
Palo Alto, CA 94306
USA
Phone
Website
Email Address
Overview
Eiger is a biopharmaceutical company developing new antiviral agents against novel targets in the treatment of hepatitis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Cory
Chief Financial Officer
Sri Ryali
VP - Bus. Development
Eldon Mayer
VP - General Counsel
Stephana Patton
VP - Sales
James Shaffer
Browse more venture capital transactions:
Prev: 2/24/2009: Rivulet Communications venture capital transaction
Next: 2/24/2009: Topaz Bridge venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. All VC database entries reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs